Boston secret stent plan alleged in Medinol fraud suit
This article was originally published in Clinica
Executive Summary
In a bizarre twist to the often acrimonious war of words surrounding negotiations between Boston Scientific and its stent supplier Medinol, Medinol has filed a lawsuit in the US. The suit has caused Boston's share dealings to be suspended. It involves not only the company, but also the senior management, including co-founder Peter Nicholas, who are accused of fraud.